The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Acute graft-versus-host disease (GvHD) affects up to 50% of patients receiving allogeneic bone marrow transplant (BMT) and is the leading cause of morbidity and mortality from BMT. While animal models suggest that donor myeloid cells play a role in the enhancement of GvHD, technical limitations of in situ microscopy prevent the precise identification of which cells infiltrate GvHD lesions. Splenic T cells are used to induce GvHD in animal models, but human BMT recipients are depleted of T cells prior to transplant to decrease graft rejection, so these may not be the sole mediators of GvHD pathology.
A study published by Laura Jardine and colleagues in the Journal of Clinical Investigation1 examined acute GvHD skin lesions, to identify which cells were present in skin explants and whether these cells were donor or recipient in origin.
Table 1. Cell surface markers used to determine cell identities1
Marker |
Cell type |
BMT, bone marrow transplant; CD, cluster of differentiation; FXIII, factor XIII |
|
CD11c |
Myeloid cells |
CD3 |
T cells |
CD163 |
Macrophages (not monocytes) |
FXIII |
Tissue resident macrophages (BMT recipient macrophages) |
Table 2. Genes upregulated in GvHD macrophages1
Class of Genes |
Genes |
CCL, C-C chemokine ligand; CD, cluster of differentiation; GvHD, graft-versus-host disease; HLA, human leukocyte antigen; IL, interleukin; RANTES, regulated upon activation, normal T cell expressed, and presumably secreted; SELPLG, selectin P ligand; SPP, secreted phosphoprotein; TAP, transporter associated with antigen processing; TNF, tumor necrosis factor |
|
Antigen presentation |
HLA TAP1 |
Cell recruitment |
CCL24 |
Lymphocyte stimulation |
CD82 |
Pro-inflammatory cytokine stimulation |
SPP1 |
Leukocyte extravasation |
SELPLG |
Cytokines and chemokines |
CCL5/RANTES, CXCL10, IL-8, TNFβ, IL-10 |
Table 3. Gene expression in GvHD PBMCs1
|
Genes |
CCR, C-C chemokine receptor; CIITA, Class II major histocompatibility complex transactivator; FCER, Fc epsilon receptor; FCGR, Fc gamma receptor; GBP, guanylate-binding proteins; GNLY, granulysin; GvHD, graft-versus-host disease; IFITM, interferon-induced transmembrane; IRF, interferon regulatory factor; MRC, macrophage mannose receptor; PBMC, peripheral blood mononuclear cell; ZBTB, zinc finger and BTB domain |
|
Upregulated |
CCR5, MRC1, FCGR3A/B, GNLY, IFITM1, GBP1 |
Downregulated |
FCER1A, IRF4, ZBTB46, CIITA |
Table 4. Genes expressed in GvHD macrophages and MLR macrophages1
|
Genes |
CCR, C-C chemokine receptor; GNLY, granulysin; GvHD, graft-versus-host disease; MLR, mixed leukocyte reaction; MRC, macrophage mannose receptor; PPBP, pro-platelet basic protein; TRAIL, TNF-related apoptosis-inducing ligand |
|
Upregulated in GvHD and MLR macrophages |
CCR5 MRC1 PPBP |
Upregulated in MLR macrophages |
Perforin Granzyme A GNLY TRAIL |
The authors found that skin biopsies from GvHD patients contain donor derived CD11c+CD14+ macrophages that potently activate T cells, and highlight that this interaction between donor macrophages and T cells has the potential to mediate pathology in the GvHD skin lesion. The authors conclude that understanding the function of these macrophages may enhance GvHD treatment and prevention options.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content